194 related articles for article (PubMed ID: 22044266)
1. Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.
Liu Y; Bajjuri KM; Liu C; Sinha SC
Mol Pharm; 2012 Jan; 9(1):168-75. PubMed ID: 22044266
[TBL] [Abstract][Full Text] [Related]
2. Chemically Programmed Bispecific Antibody Targeting Legumain Protease and αvβ3 Integrin Mediates Strong Antitumor Effects.
Liu Y; Goswami RK; Liu C; Sinha SC
Mol Pharm; 2015 Jul; 12(7):2544-50. PubMed ID: 26024761
[TBL] [Abstract][Full Text] [Related]
3. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain.
Stern L; Perry R; Ofek P; Many A; Shabat D; Satchi-Fainaro R
Bioconjug Chem; 2009 Mar; 20(3):500-10. PubMed ID: 19196156
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Jayle C; Alsarraf J; Thomas M; Papot S
Eur J Med Chem; 2013 Sep; 67():75-80. PubMed ID: 23845743
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the anti-cervical cancer effect of a prodrug ：CBZ-AAN-DOX with hypoxic cell culture and tumor-bearing zebrafish models.
Chen HC; Rui W; You SY; Liu XW; Huang J; Chen HY
Exp Cell Res; 2020 Jun; 391(1):111980. PubMed ID: 32229193
[TBL] [Abstract][Full Text] [Related]
6. α
Zhong P; Gu X; Cheng R; Deng C; Meng F; Zhong Z
Int J Nanomedicine; 2017; 12():7913-7921. PubMed ID: 29138558
[TBL] [Abstract][Full Text] [Related]
7. CPI-0004Na, a new doxorubicin prodrug, reduces growth of 3LL-H61 carcinoma lung metastases in C57BI/6 mice.
Dasnois L; Lebtahi K; Abarca-Quinones J; Havaux N; Dupont S; Dubois V; Trouet A
J Exp Ther Oncol; 2004 Jul; 4(2):167-9. PubMed ID: 15500012
[TBL] [Abstract][Full Text] [Related]
8. The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.
Legigan T; Clarhaut J; Tranoy-Opalinski I; Monvoisin A; Renoux B; Thomas M; Le Pape A; Lerondel S; Papot S
Angew Chem Int Ed Engl; 2012 Nov; 51(46):11606-10. PubMed ID: 22996951
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast Activation Protein α Activated Tripeptide Bufadienolide Antitumor Prodrug with Reduced Cardiotoxicity.
Deng LJ; Wang LH; Peng CK; Li YB; Huang MH; Chen MF; Lei XP; Qi M; Cen Y; Ye WC; Zhang DM; Chen WM
J Med Chem; 2017 Jul; 60(13):5320-5333. PubMed ID: 28595013
[TBL] [Abstract][Full Text] [Related]
10. A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM
Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug.
de Groot FM; Broxterman HJ; Adams HP; van Vliet A; Tesser GI; Elderkamp YW; Schraa AJ; Kok RJ; Molema G; Pinedo HM; Scheeren HW
Mol Cancer Ther; 2002 Sep; 1(11):901-11. PubMed ID: 12481411
[TBL] [Abstract][Full Text] [Related]
12. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
[TBL] [Abstract][Full Text] [Related]
13. An activatable prodrug for the treatment of metastatic tumors.
Kim EJ; Bhuniya S; Lee H; Kim HM; Cheong C; Maiti S; Hong KS; Kim JS
J Am Chem Soc; 2014 Oct; 136(39):13888-94. PubMed ID: 25238144
[TBL] [Abstract][Full Text] [Related]
14. Direct Real-Time Monitoring of Prodrug Activation by Chemiluminescence.
Gnaim S; Scomparin A; Das S; Blau R; Satchi-Fainaro R; Shabat D
Angew Chem Int Ed Engl; 2018 Jul; 57(29):9033-9037. PubMed ID: 29786931
[TBL] [Abstract][Full Text] [Related]
15. Legumain correlates with neuroblastoma differentiation and can be used in prodrug design.
Zhang M; Jiang Z; Chen S; Wu Z; Chen K; Wu Y
Chem Biol Drug Des; 2018 Feb; 91(2):534-544. PubMed ID: 28994241
[TBL] [Abstract][Full Text] [Related]
16. Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247.
Shannon KE; Keene JL; Settle SL; Duffin TD; Nickols MA; Westlin M; Schroeter S; Ruminski PG; Griggs DW
Clin Exp Metastasis; 2004; 21(2):129-38. PubMed ID: 15168730
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of a novel legumain-cleavable colchicine prodrug with cell-specific toxicity.
Smith RL; Åstrand OA; Nguyen LM; Elvestrand T; Hagelin G; Solberg R; Johansen HT; Rongved P
Bioorg Med Chem; 2014 Jul; 22(13):3309-15. PubMed ID: 24842619
[TBL] [Abstract][Full Text] [Related]
18. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
19. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
20. Highly potent monomethyl auristatin E prodrug activated by caspase-3 for the chemoradiotherapy of triple-negative breast cancer.
Chung SW; Cho YS; Choi JU; Kim HR; Won TH; Kim SY; Byun Y
Biomaterials; 2019 Feb; 192():109-117. PubMed ID: 30447398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
